The present disclosure is directed to a powdered formulation comprising an analgesic for use in pulmonary inhalation administration for the rapid analgesic titration of pain, in particular breakthrough pain. Upon administration, the powdered formulation is able to provide a narrower titration range in patients suffering from pain, as well as effective analgesic amounts in a shorter time and at lower dose levels when compared to the analgesic administered by an oral transmucosal route.
展开▼